Summer 2001
Page 1 to 8 of 8 |
Unrealised wealth in the avalanche of science By Dr Benjamin P. Chen Summer 2001
The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora’s box of intellectual properties opened as a result is beyond any one company’s capability to fully develop. Given the escalating cost of pharmaceutical R&D, increased productivity and return from pharmaceutical assets is critical. A key success factor for any company in life sciences is to balance internal drug development effort with active licensing activities to fully derive value of drug leads generated as a result of the avalanche of science.

Read More

Surrogate endpoints IN CANCER TRIALS By Professor Karol Sikora Summer 2001
Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article discusses how we urgently need surrogate endpoints to enhance the speed of assessment in the development of drugs in this presently under-researched area and the potential benefits they can bring such as lowering costs, reducing time to NDA, bypassing need for phase II studies and reviving dead drugs.

Read More

STEM CELLS the long march forward to the clinic By Dr Alan Colman Summer 2001
The area of cellular therapeutics has never been readily embraced by ‘Big Pharma’, with ethical and regulatory issues even more complex and troublesome than proteins. Can stem cell therapy provide the key to unlocking a rich vein of pharmaceutical activity?

Read More

PROTEIN ARRAYS new technology for the proteomics era By Dr Jeffrey P. Kiplinger Summer 2001
The study of the human proteome will drive drug discovery in coming years; although how, when, and in what direction are a little uncertain at present. To build understanding of the role of the human protein complement in health, development, and disease, a database more complex than the human genetic sequence is under construction. To face the challenge, new technologies for protein analysis must be developed that are faster and provide more information than current approaches.

Read More

PHARMACOGENETICS a review of concepts and contents By Professor Klaus Lindpaintner Summer 2001
Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation?

Read More

Patenting the tools of drug discovery By Dr Jorge A. Goldstein Summer 2001
Many patents containing claims on drug discovery tools have been issued or are pending, including patents on: 1) cDNA fragments; 2) Crystallised receptors, especially their use in software related rational drug design methods; and 3) Target genes/proteins and their uses in screening and in mechanistic therapeutic applications. This article discusses these patents, the US PTO’s views on the utility of their claims and their potential court interpretation

Read More

Outsourcing life science informatics solutions By Dr Steve Gardner sUMMER 2001
The life science industry depends on information gathered from new technologies for productivity and competitive advantage in the R&D process. As more information is gathered and the systems become more complex, building and maintaining data management solutions that support rapid and accurate decision-making becomes harder. This article examines ways in which strategic outsourcing of elements of the life science informatics systems can enable companies to apply their resources where they can generate most competitive advantage.

Read More

Health economic considerations for early drug discovery By Dr Ann-Marie Craig and Dr Lisa Kennedy Summer 2001
The use of health economics in early phase development, while not an exact science, can, when conjoined with clinical evidence, be a very valuable information tool enabling companies to identify whether there is a market worth pursuing while identifying issues that need to addressed in future trials and for launch.

Read More

Summer 2001
Page 1 to 8 of 8 |